What Is Actually Changing In PacBio’s Fair Value Story? Analysts have lifted their fair value estimate for Pacific ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism, led by decent second-quarter 2024 earnings ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q2 CY2025 results , with sales up 10.4% year on year to $39.77 million. Its non-GAAP loss of $0.13 per share was 21.5% above ...

PacBio expands product adoption, introducing Revio and Onso, enhancing market and technological reach. Despite 10% growth since 2015, dilution eroded shareholder value; pivot possible with 25% growth ...

Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener TipRanks is the ...

PacBio CEO Christian Henry Pacific Biosciences of California (PacBio) has landed the short-read sequencing capabilities it has long sought to combine with its strength in long reads by agreeing to ...

MENLO PARK, Calif. - PacBio (NASDAQ:PACB), a $486.6 million market cap biotechnology company, announced Tuesday a series of innovations for its Revio and Vega sequencing platforms that could reduce ...